Technical Analysis for IMMU - Immunomedics, Inc.

Grade Last Price % Change Price Change
grade B 21.2 1.00% 0.21
IMMU closed up 1.0 percent on Monday, May 21, 2018, on 1.46 times normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical IMMU trend table...

Date Alert Name Type % Chg
May 21 New 52 Week Closing High Bullish 0.00%
May 21 Calm After Storm Range Contraction 0.00%
May 21 Upper Bollinger Band Walk Strength 0.00%
May 21 Up 3 Days in a Row Strength 0.00%
May 21 Up 4 Days in a Row Strength 0.00%
May 21 Upper Bollinger Band Touch Strength 0.00%
May 18 New 52 Week Closing High Bullish 1.00%
May 18 Jack-in-the-Box Bullish Bullish Swing Setup 1.00%
May 18 Calm After Storm Range Contraction 1.00%
May 18 NR7 Range Contraction 1.00%

Older signals for IMMU ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company's products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with Nycomed GmbH and UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Is IMMU a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 22.51
52 Week Low 7.17
Average Volume 2,102,073
200-Day Moving Average 13.9542
50-Day Moving Average 16.8232
20-Day Moving Average 18.5675
10-Day Moving Average 19.495
Average True Range 1.0206
ADX 40.77
+DI 45.66
-DI 8.6
Chandelier Exit (Long, 3 ATRs ) 19.4482
Chandelier Exit (Short, 3 ATRs ) 18.6318
Upper Bollinger Band 21.3209
Lower Bollinger Band 15.8141
Percent B (%b) 0.98
BandWidth 29.658274
MACD Line 1.0905
MACD Signal Line 0.8483
MACD Histogram 0.2423
Fundamentals Value
Market Cap 2.36 Billion
Num Shares 111 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -14.42
Price-to-Sales 396.34
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.30
Resistance 3 (R3) 22.28 21.91 22.11
Resistance 2 (R2) 21.91 21.63 21.91 22.05
Resistance 1 (R1) 21.55 21.46 21.37 21.57 21.99
Pivot Point 21.18 21.18 21.08 21.18 21.18
Support 1 (S1) 20.82 20.90 20.64 20.84 20.41
Support 2 (S2) 20.45 20.73 20.45 20.35
Support 3 (S3) 20.09 20.45 20.29
Support 4 (S4) 20.11